Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | 11.4% | 17.5% |
| 2024 | 85.6% | -10.8% | -10.2% |
| 2023 | 79.1% | -9.3% | 5.2% |
| 2022 | 89.6% | 4.4% | 83.3% |
| 2021 | 76.4% | -406.4% | -409.7% |
Download Data
Export KNSA earnings history in CSV or JSON format
Free sign-in required to download data
Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings Overview
As of February 28, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) reported trailing twelve-month net income of $119M, reflecting +2.3% year-over-year growth. The company earned $1.50 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, KNSA's historical earnings data spans multiple years. The company achieved its highest annual net income of $183M in fiscal 2022.
Kiniksa Pharmaceuticals, Ltd. maintains positive profitability with, operating margin of 0.1%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), KNSA has room to improve margins relative to the peer group. Compare KNSA vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $119M | +374.9% | $77M | $0.75 | 17.5% | 11.4% |
| 2024 | -$43M | -406.7% | -$46M | $-0.60 | -10.2% | -10.8% |
| 2023 | $14M | -92.3% | -$25M | $0.20 | 5.2% | -9.3% |
| 2022 | $183M | +216.1% | $10M | $2.60 | 83.3% | 4.4% |
| 2021 | -$158M | +2.1% | -$157M | $-2.30 | -409.7% | -406.4% |
| 2020 | -$161M | +0.3% | -$157M | $-2.61 | - | - |
| 2019 | -$162M | -56.8% | -$170M | $-2.99 | - | - |
| 2018 | -$103M | -59.1% | -$108M | $-3.49 | - | - |
| 2017 | -$65M | -170.6% | -$65M | $-2.00 | - | - |
| 2016 | -$24M | - | -$24M | $-0.74 | - | - |
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare KNSA vs AGIO
See how KNSA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is KNSA growing earnings?
KNSA EPS of $1.50 reflects slowing growth at +2.3%, below the 5-year CAGR of N/A. TTM net income is $119M. Expansion rate has moderated.
What are KNSA's profit margins?
Kiniksa Pharmaceuticals, Ltd. net margin is +0.2%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are KNSA's earnings?
KNSA earnings data spans 2016-2025. The current earnings trend is +2.3% YoY. Historical data enables comparison across business cycles.